How to build a Successful Biotech company in Europe with Joern Aldag

11/07/2016 - 6 minutes

Joern Aldag is one of the impressive Biotech leaders in Europe. Hearing him at our Refresh conference made me think of a new type of article we could publish: a detailed summary of the lessons learned from such a very rich career. Here’s the first of such a piece.

Aldag was just appointed CEO of the Vienna-based Oncology Biotech Hookipa. He is also board member of Boston-based Unum Therapeutics (an example of a next generation CAR-T biotech) and Chairman of Molecular Partners (one of the most successful Biotech in Zurich).

Previously, he was the CEO of German Evotec, bringing the company from 30 to 400 employees, before he then headed uniQure where he got the world’s first market approval for a Gene Therapy and also brought the company onto the NASDAQ.Joern Aldag Biotech Uniqure Hookipa Molecular Evotec


How did you bring Evotec from 30 to 400 employees?

When I joined Evotec in 1997, it was mainly a technology provider and a CRO.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member